Image_2_Maternal 25-Hydroxyvitamin D Deficiency Promoted Metabolic Syndrome and Downregulated Nrf2/CBR1 Pathway in Offspring.jpeg
Metabolic syndrome is a disorder of energy use and storage, which is characterized by central obesity, dyslipidemia, and raised blood pressure and blood sugar levels. Maternal 25-hydroxyvitamin D deficiency is known to cause metabolic changes, chronic disease, and increased adiposity in adulthood. However, the underlying mechanism of induced metabolic syndrome (MetS) in the offspring in vitamin D deficient pregnant mothers remains unclear. We identified that maternal 25-hydroxyvitamin D deficiency enhances oxidative stress, which leads to the development of MetS in the mother and her offspring. Further, immunohistochemical, Western blotting, and qRT-PCR analyses revealed that maternal 25-hydroxyvitamin D deficiency inhibited the activation of the Nrf2/carbonyl reductase 1 (CBR1) pathway in maternal placenta, liver, and pancreas, as well as the offspring's liver and pancreas. Further analyses uncovered that application of 25-hydroxyvitamin D activated the Nrf2/CBR1 pathway, relieving the oxidative stress in BRL cells, suggesting that 25-hydroxyvitamin D regulates oxidative stress in offspring and induces the activation of the Nrf2/CBR1 pathway. Taken together, our study finds that maternal 25-hydroxyvitamin D deficiency is likely to result in offspring's MetS probably via abnormal nutrition transformation across placenta. Depression of the Nrf2/CBR1 pathway in both mothers and their offspring is one of the causes of oxidative stress leading to MetS. This study suggests that 25-hydroxyvitamin D treatment may relieve the offspring's MetS.
History
References
- https://doi.org//10.1136/bmj.f1169
- https://doi.org//10.3389/fped.2017.00069
- https://doi.org//10.1016/j.ejphar.2013.10.023
- https://doi.org//10.1016/j.placenta.2013.07.063
- https://doi.org//10.1016/0140-6736(93)91224-a
- https://doi.org//10.1152/physrev.00029.2015
- https://doi.org//10.3390/nu7042748
- https://doi.org//10.3389/fphar.2018.01027
- https://doi.org//10.1136/bmj.f5703
- https://doi.org//10.1093/bmb/ldy010
- https://doi.org//10.1111/ijpo.12267
- https://doi.org//10.1371/journal.pone.0099005
- https://doi.org//10.1016/j.lfs.2016.02.089
- https://doi.org//10.1080/10715769900300881
- https://doi.org//10.1016/j.imlet.2019.06.012
- https://doi.org//10.1146/annurev.pharmtox.46.120604.141046
- https://doi.org//10.1016/j.jprot.2010.03.018
- https://doi.org//10.1016/j.jacc.2008.08.050
- https://doi.org//10.1016/j.ijcard.2013.08.001
- https://doi.org//10.4330/wjc.v6.i6.462
- https://doi.org//10.1016/j.cbi.2012.11.023
- https://doi.org//10.1093/ajh/hpt160
- https://doi.org//10.1074/jbc.R900010200
- https://doi.org//10.4274/jcrpe.4706
- https://doi.org//10.1016/j.ejim.2012.01.007
- https://doi.org//10.1016/j.ecl.2013.09.009
- https://doi.org//10.1159/000441810
- https://doi.org//10.1016/j.ejphar.2009.08.022
- https://doi.org//10.1073/pnas.0707258104
- https://doi.org//10.1124/jpet.107.135822
- https://doi.org//10.3945/jn.116.239475
- https://doi.org//10.3109/14767058.2013.765849
- https://doi.org//10.1152/ajpendo.1987.253.6.E675
- https://doi.org//10.1093/toxsci/kfr183
- https://doi.org//10.2337/db12-0584
- https://doi.org//10.1038/s41598-018-19838-5
- https://doi.org//10.1007/s00125-014-3316-7
- https://doi.org//10.18632/oncotarget.7568
- https://doi.org//10.1111/jdi.12928
- https://doi.org//10.1111/1750-3841.13856